Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo. Nano Lett 2010 Dec 08;10(12):4920-8
Date
11/26/2010Pubmed ID
21090693Pubmed Central ID
PMC4089981DOI
10.1021/nl102889yScopus ID
2-s2.0-78650080865 (requires institutional sign-in at Scopus site) 156 CitationsAbstract
Nanoparticle-based therapeutics with local delivery and external electromagnetic field modulation holds extraordinary promise for soft-tissue cancers such as breast cancer; however, knowledge of the distribution and fate of nanoparticles in vivo is crucial for clinical translation. Here we demonstrate that multiple diagnostic capabilities can be introduced in photothermal therapeutic nanocomplexes by simultaneously enhancing both near-infrared fluorescence and magnetic resonance imaging (MRI). We track nanocomplexes in vivo, examining the influence of HER2 antibody targeting on nanocomplex distribution over 72 h. This approach provides valuable, detailed information regarding the distribution and fate of complex nanoparticles designed for specific diagnostic and therapeutic functions.
Author List
Bardhan R, Chen W, Bartels M, Perez-Torres C, Botero MF, McAninch RW, Contreras A, Schiff R, Pautler RG, Halas NJ, Joshi AAuthor
Amit Joshi PhD Professor in the Biomedical Engineering department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsBreast Neoplasms
Cell Line, Tumor
Electromagnetic Fields
Female
Fluorescence
Humans
Magnetic Resonance Imaging
Mice
Nanoparticles
Spectroscopy, Near-Infrared
